XOMA to Present at 24th Annual JP Morgan Healthcare Conference
Wednesday January 4, 4:00 pm ET
BERKELEY, Calif.--(BUSINESS WIRE)--Jan. 4, 2006--XOMA Ltd. (Nasdaq:XOMA - News) announced today that John L. Castello, XOMA's chairman, president and chief executive officer, and Bob Gundel, Ph.D., vice president of scientific corporate development, will present an overview of XOMA's business strategy and update of the company's pipeline and collaborations at the 24th Annual JP Morgan Healthcare Conference at the Westin, St. Francis Hotel in San Francisco, CA on Wednesday, January 11, 2006 at 8:00 a.m. Pacific time, followed by a breakout question and answer session at 8:30 a.m., Pacific time.
An audio webcast of the presentation will be available live, and can be accessed via a link on the XOMA website at xoma.com. An archived version of the webcast will be available through the XOMA website until January 31, 2006.
About XOMA
XOMA is a leader in therapeutic antibodies, with a focus on cancer and immune diseases. XOMA has a royalty interest in RAPTIVA® (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis. XOMA's discovery and development capabilities include antibody phage display, bacterial cell expression, and Human Engineering(TM) technologies, plus a fully integrated drug development and manufacturing infrastructure. XOMA's development collaborators include Chiron Corporation and Lexicon Genetics Incorporated. The company pipeline also includes proprietary programs in preclinical and clinical development. |
